Current Status of the Oral Delivery of Insulin

Insulin is one of the most popular proteins to be studied for oral delivery. The authors review the current status of the development strategies of insulin drug delivery systems, the various challenges associated with these systems, and how these challenges may be overcome.

Articles in this issue

---

Outsourcing Outlook

Effects of Polyethylene Glycol on Morphology, Thermomechanical Properties, and Water Vapor Permeability of Cellulose Acetate-Free Films

Hydrogels for the Controlled Release of Pharmaceutical Proteins

Near-Infrared Inspection Complements Other QC Systems

Safety and Manufacturing Standards

System Optimization for In Situ Fiber-Optic Dissolution Testing: Hydrodynamic Effects, System Performance, and Applications

Current Status of the Oral Delivery of Insulin

Laboratory Equipment Qualification

Filter Integrity Testing in Liquid Applications, Revisited, Part I

360&#176 Feedback &#45 Improving the Selection Process All the Way Around

Entering into an Alliance with Big Pharma: Benchmarks for Drug Delivery Contract Service Providers

Related Videos

Related Content

Advertisement

July 25th 2025

EMA Approves Lower GWP Alternative for Inhalation Medicine

Susan Haigney

The agency has given a positive recommendation for a change in the gas propellant in Trixeo Aerosphere and Riltrava Aerosphere that will have a 1000-fold reduction in global warming potential compared to the current propellant.

April 30th 2024

Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines

Feliza Mirasol

In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.

July 23rd 2025

Overcoming PK/PD Modeling Challenges

Cynthia A. Challener

Artificial intelligence and machine learning can help identify complex patterns.

March 26th 2024

Drug Solutions Podcast: Applying Appropriate Analytics to Drug Development

In this episode of the Drug Solutions Podcast, Jan Bekker, Vice President of Business Development, Commercial and Technical Operations at BioCina, discusses the latest analytical tools and their applications in the drug development market.

July 22nd 2025

Bristol Myers Squibb Application for Psoriatic Arthritis Drug Accepted for Review in Four Regions

Patrick Lavery

Sotyktu (deucravacitinib) has been assigned a Prescription Drug User Fee Act (PDUFA) goal date of March 6, 2026.

July 21st 2025

FDA Appoints New CDER Director, George Tidmarsh

Susan Haigney

George Francis Tidmarsh, MD, PhD, founding co-director of Stanford’s Master of Translational Research and Applied Medicine program, has been appointed as the new director of the Center for Drug Evaluation and Research.

Related Content

Advertisement

July 25th 2025

EMA Approves Lower GWP Alternative for Inhalation Medicine

Susan Haigney

The agency has given a positive recommendation for a change in the gas propellant in Trixeo Aerosphere and Riltrava Aerosphere that will have a 1000-fold reduction in global warming potential compared to the current propellant.

April 30th 2024

Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines

Feliza Mirasol

In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.

July 23rd 2025

Overcoming PK/PD Modeling Challenges

Cynthia A. Challener

Artificial intelligence and machine learning can help identify complex patterns.

March 26th 2024

Drug Solutions Podcast: Applying Appropriate Analytics to Drug Development

In this episode of the Drug Solutions Podcast, Jan Bekker, Vice President of Business Development, Commercial and Technical Operations at BioCina, discusses the latest analytical tools and their applications in the drug development market.

July 22nd 2025

Bristol Myers Squibb Application for Psoriatic Arthritis Drug Accepted for Review in Four Regions

Patrick Lavery

Sotyktu (deucravacitinib) has been assigned a Prescription Drug User Fee Act (PDUFA) goal date of March 6, 2026.

July 21st 2025

FDA Appoints New CDER Director, George Tidmarsh

Susan Haigney

George Francis Tidmarsh, MD, PhD, founding co-director of Stanford’s Master of Translational Research and Applied Medicine program, has been appointed as the new director of the Center for Drug Evaluation and Research.